DCDC1

Summary

DCDC1 (doublecortin domain containing 1, HGNC:20625) is a protein-coding gene on chromosome 11p14.1, encoding Doublecortin domain-containing protein 1 (M0R2J8). Microtubule-binding protein which plays an important role in mediating dynein-dependent transport of RAB8A-positive vesicles to the midbody during cytokinesis.

This gene encodes a member of the doublecortin family. The protein encoded by this gene is a hydrophilic, intracellular protein. It contains a single doublecortin domain and is unable to bind microtubules and to regulate microtubule polymerization. This gene is mainly expressed in adult testis. It does not have a mouse homolog.

Source: NCBI Gene 341019 — RefSeq curated summary.

At a glance

• GWAS associations: 49
• Clinical variants (ClinVar): 158 total — 9 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_001387274

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20625
Approved symbol	DCDC1
Name	doublecortin domain containing 1
Location	11p14.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ46154
Ensembl gene	ENSG00000170959
Ensembl biotype	protein_coding
OMIM	608062
Entrez	341019

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 4 protein_coding, 3 nonsense_mediated_decay, 3 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000303697, ENST00000342355, ENST00000406071, ENST00000429306, ENST00000437348, ENST00000444572, ENST00000452803, ENST00000483396, ENST00000534021, ENST00000534722, ENST00000597505, ENST00000684477

RefSeq mRNA: 5 — MANE Select: NM_001387274 NM_001367979, NM_001387274, NM_001387275, NM_020869, NM_181807

CCDS: CCDS73270, CCDS7872, CCDS91453, CCDS91454

Canonical transcript exons

ENST00000684477 — 39 exons

Exon	Start	End
ENSE00001167097	30903482	30903683
ENSE00001167106	30904961	30905164
ENSE00001600541	31290647	31290852
ENSE00001613815	31328117	31328286
ENSE00001731410	31305615	31305777
ENSE00001744372	30863603	30865332
ENSE00001763121	31306232	31306388
ENSE00001787325	31335447	31335564
ENSE00001803070	31307639	31307908
ENSE00003473183	31094050	31094184
ENSE00003475096	30892818	30892997
ENSE00003476096	30894248	30894384
ENSE00003492134	30906540	30906725
ENSE00003503553	30878544	30878711
ENSE00003511130	31241450	31241616
ENSE00003517532	31077865	31077925
ENSE00003523482	30952445	30952568
ENSE00003523814	31091393	31091511
ENSE00003524020	31106797	31106960
ENSE00003536653	30920776	30920935
ENSE00003538444	30915511	30915711
ENSE00003546970	30881158	30881308
ENSE00003548711	30931771	30931952
ENSE00003564393	31065019	31065153
ENSE00003583307	31137692	31137784
ENSE00003603613	31064469	31064626
ENSE00003612667	30911327	30911420
ENSE00003614373	31110260	31110361
ENSE00003625137	31127469	31127639
ENSE00003638124	30922503	30922638
ENSE00003643087	30916870	30917028
ENSE00003647744	31103644	31103769
ENSE00003651401	31265507	31265600
ENSE00003674446	30900346	30900498
ENSE00003675918	31102177	31102282
ENSE00003677710	30899541	30899642
ENSE00003690392	30925309	30925408
ENSE00003718407	30908946	30909116
ENSE00003916493	31369697	31369739

Expression profiles

Bgee: expression breadth ubiquitous, 148 present calls, max score 84.70.

FANTOM5 (CAGE): breadth broad, TPM avg 1.1098 / max 98.1801, expressed in 310 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
119127	1.0456	296
119122	0.0384	10
119123	0.0258	10

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oviduct epithelium	UBERON:0004804	84.70	gold quality
right uterine tube	UBERON:0001302	83.81	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.91	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.03	gold quality
bronchial epithelial cell	CL:0002328	79.30	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	78.28	gold quality
bronchus	UBERON:0002185	77.56	gold quality
mucosa of paranasal sinus	UBERON:0005030	77.18	gold quality
fallopian tube	UBERON:0003889	70.48	gold quality
right lobe of liver	UBERON:0001114	70.22	gold quality
ventricular zone	UBERON:0003053	69.88	gold quality
gall bladder	UBERON:0002110	69.80	gold quality
left testis	UBERON:0004533	68.00	gold quality
testis	UBERON:0000473	67.64	gold quality
right testis	UBERON:0004534	67.39	gold quality
pituitary gland	UBERON:0000007	66.83	gold quality
adenohypophysis	UBERON:0002196	66.22	gold quality
islet of Langerhans	UBERON:0000006	65.66	gold quality
calcaneal tendon	UBERON:0003701	65.49	gold quality
liver	UBERON:0002107	64.77	gold quality
epithelium of nasopharynx	UBERON:0001951	63.81	gold quality
cerebellar vermis	UBERON:0004720	61.24	gold quality
thyroid gland	UBERON:0002046	60.76	gold quality
left lobe of thyroid gland	UBERON:0001120	60.65	gold quality
corpus callosum	UBERON:0002336	59.46	gold quality
nasal cavity mucosa	UBERON:0001826	59.42	gold quality
right lobe of thyroid gland	UBERON:0001119	58.46	gold quality
right lung	UBERON:0002167	58.24	gold quality
metanephros cortex	UBERON:0010533	58.11	gold quality
ganglionic eminence	UBERON:0004023	58.05	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.92
E-MTAB-9388	yes	6.54

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

23 targeting DCDC1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-7157-5P	99.66	69.33	1829
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-4708-3P	99.51	67.99	870
HSA-MIR-208A-5P	99.42	70.83	1913
HSA-MIR-208B-5P	99.42	70.83	1952
HSA-MIR-548V	99.29	69.47	1157
HSA-MIR-376A-3P	99.06	69.17	1128
HSA-MIR-376B-3P	99.06	69.17	1128
HSA-MIR-10524-5P	99.05	66.08	963
HSA-MIR-6506-5P	99.04	65.66	1386
HSA-MIR-1207-3P	98.99	66.22	1532
HSA-MIR-2115-5P	98.66	68.07	1191
HSA-MIR-619-5P	98.57	64.97	1988
HSA-MIR-4691-5P	98.41	66.77	1343
HSA-MIR-6792-3P	98.41	66.86	1359
HSA-MIR-4799-3P	97.78	65.97	893
HSA-MIR-4314	97.50	67.30	1369
HSA-MIR-4720-5P	97.46	65.67	893
HSA-MIR-5588-5P	97.46	65.70	913

Literature-anchored findings (GeneRIF, showing 2)

• DCDC1 was mapped to 11p13; mainly expressed in adult testis; and its expression in fetal brain was much higher than in adult brain (PMID:12820024)
• DCDC5 colocalizes with Rab8 and links it to dynein during cytokinesis. DCDC5 knockdown increased apoptosis and the number of multinucleated cells. (PMID:22159412)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Doublecortin domain-containing protein 1 — M0R2J8 (reviewed: M0R2J8)

Alternative names: Doublecortin domain-containing 5 protein

All UniProt accessions (5): A0A804HJA9, B6ZDN3, M0R2J8, H0Y2Q8, H7C298

UniProt curated annotations — full annotation on UniProt →

Function. Microtubule-binding protein which plays an important role in mediating dynein-dependent transport of RAB8A-positive vesicles to the midbody during cytokinesis.

Subunit / interactions. Interacts with dynein intermediate chain, tubulin, RAB8A, RAB3IP, NUDC, PAFAH1B1 and DCTN1.

Subcellular location. Midbody. Midbody ring. Cytoplasm. Cytoskeleton. Spindle.

Isoforms (3)

UniProt ID	Names	Canonical?
M0R2J8-1	1	yes
M0R2J8-2	2
M0R2J8-3	3

RefSeq proteins (5): NP_001354908, NP_001374203, NP_001374204, NP_065920, NP_861523 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003533	Doublecortin_dom	Domain
IPR035992	Ricin_B-like_lectins	Homologous_superfamily
IPR036572	Doublecortin_dom_sf	Homologous_superfamily
IPR043188	DCDC1	Family
IPR056415	DCX2_DCDC1	Domain
IPR057424	Ubiquitin_DCDC1	Domain

Pfam: PF24478, PF25510

UniProt features (15 total): domain 4, splice variant 4, sequence variant 2, region of interest 2, chain 1, sequence conflict 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-M0R2J8-F1	68.53	0.12

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 116 (showing top): GOBP_MITOTIC_CYTOKINESIS, AATGGAG_MIR136, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, NKX61_01, CDP_01, CAGCAGG_MIR370, GOBP_CYTOKINESIS, GOBP_REGULATION_OF_CELL_CYCLE, IRF1_Q6, GOBP_REGULATION_OF_CYTOKINESIS, GOBP_REGULATION_OF_CELL_DIVISION, ARGGGTTAA_UNKNOWN, TGACATY_UNKNOWN, GOBP_MITOTIC_CELL_CYCLE, HAND1E47_01

GO Biological Process (3): intracellular signal transduction (GO:0035556), cell division (GO:0051301), regulation of mitotic cytokinesis (GO:1902412)

GO Molecular Function (3): microtubule binding (GO:0008017), carbohydrate binding (GO:0030246), protein binding (GO:0005515)

GO Cellular Component (7): microtubule (GO:0005874), midbody (GO:0030496), mitotic spindle (GO:0072686), Flemming body (GO:0090543), cytoplasm (GO:0005737), spindle (GO:0005819), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
intracellular anatomical structure	2
binding	2
microtubule cytoskeleton	2
intracellular membraneless organelle	2
signal transduction	1
cellular process	1
mitotic cytokinesis	1
regulation of cytokinesis	1
tubulin binding	1
polymeric cytoskeletal fiber	1
spindle	1
midbody	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

3 interactions, top by confidence:

A	B	Type	Score
DCDC1	KRT8	psi-mi:“MI:0915”(physical association)	0.400
DCDC1	PCDH7	psi-mi:“MI:0914”(association)	0.350

ESM2 similar proteins: A2VDJ0, A5D791, A9CB18, D3YYM4, D5K8A9, E7FKV8, F1LW30, M0R2J8, O60383, O70173, O75747, Q07105, Q08DV9, Q2F7Z7, Q3MJ13, Q3SXY7, Q3T0Q2, Q3U3D7, Q3U3S3, Q4R8C8, Q5F479, Q5R800, Q5RFQ4, Q5SUS0, Q5XX13, Q6IRU7, Q6P4T1, Q6UXZ4, Q7TP65, Q8BLA1, Q8K1S2, Q8NDB2, Q8NEM2, Q8QHJ9, Q8R526, Q8TDX9, Q920I9, Q96KN7, Q9BXS4, Q9D0L6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

158 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	9
Likely pathogenic	1
Uncertain significance	78
Likely benign	26
Benign	29

Top pathogenic / likely-pathogenic (10)

Variant ID	HGVS	Classification
146313	GRCh38/hg38 11p13(chr11:31299323-31790071)x1	Pathogenic
151268	GRCh38/hg38 11p13(chr11:31189295-31701133)x1	Pathogenic
253466	GRCh37/hg19 11p13(chr11:31284306-32458309)x1	Pathogenic
267197	NC_000011.10:g.31130456_31671718del	Pathogenic
267198	NC_000011.10:g.31256273_31773692del	Pathogenic
3063225	GRCh37/hg19 11p13(chr11:31158395-31677662)x1	Pathogenic
376752	GRCh37/hg19 11p13(chr11:31147306-31714853)x1	Pathogenic
376754	GRCh37/hg19 11p13(chr11:31186493-31698208)x1	Pathogenic
376758	GRCh37/hg19 11p13(chr11:31083877-31704548)x1	Pathogenic
3256951	NM_001387274.1(DCDC1):c.5097C>A (p.Cys1699Ter)	Likely pathogenic

SpliceAI

2324 predictions. Top by Δscore:

Variant	Effect	Δscore
11:31263521:A:C	acceptor_gain	1.0000
11:31305609:TTTTA:T	donor_loss	1.0000
11:31305610:TTTA:T	donor_loss	1.0000
11:31305611:TTA:T	donor_loss	1.0000
11:31305612:TAC:T	donor_loss	1.0000
11:31305613:ACC:A	donor_loss	1.0000
11:31305614:C:CA	donor_loss	1.0000
11:31305650:C:CA	donor_gain	1.0000
11:31305773:AGCAG:A	acceptor_gain	1.0000
11:31305774:GCAG:G	acceptor_gain	1.0000
11:31305775:CAG:C	acceptor_gain	1.0000
11:31305775:CAGC:C	acceptor_gain	1.0000
11:31305776:AG:A	acceptor_gain	1.0000
11:31305776:AGC:A	acceptor_loss	1.0000
11:31305777:GCTAG:G	acceptor_loss	1.0000
11:31305778:C:CC	acceptor_gain	1.0000
11:31305778:CTAG:C	acceptor_loss	1.0000
11:31306216:TTGGA:T	donor_gain	1.0000
11:31307905:CTCT:C	acceptor_gain	1.0000
11:31345668:T:TA	donor_gain	1.0000
11:31369695:A:AC	donor_gain	1.0000
11:31369696:C:CC	donor_gain	1.0000
11:31265599:ACCTG:A	acceptor_gain	0.9900
11:31265600:CC:C	acceptor_loss	0.9900
11:31265600:CCTG:C	acceptor_gain	0.9900
11:31265600:CCTGT:C	acceptor_gain	0.9900
11:31265601:CT:C	acceptor_loss	0.9900
11:31265603:G:C	acceptor_gain	0.9900
11:31265603:G:GC	acceptor_gain	0.9900
11:31265607:A:T	acceptor_gain	0.9900

AlphaMissense

11736 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:30915533:A:G	W1211R	0.992
11:30915533:A:T	W1211R	0.992
11:30909077:A:G	W1263R	0.991
11:30909077:A:T	W1263R	0.991
11:30952477:A:G	W895R	0.990
11:30952477:A:T	W895R	0.990
11:30952567:A:G	W865R	0.990
11:30952567:A:T	W865R	0.990
11:30952498:A:G	W888R	0.987
11:30952498:A:T	W888R	0.987
11:30952528:A:G	W878R	0.984
11:30952528:A:T	W878R	0.984
11:31305659:A:T	V237D	0.984
11:31305721:G:C	F216L	0.983
11:31305721:G:T	F216L	0.983
11:31305723:A:G	F216L	0.983
11:30931943:A:G	W909R	0.982
11:30931943:A:T	W909R	0.982
11:30931947:A:C	F907L	0.981
11:30931947:A:T	F907L	0.981
11:30931949:A:G	F907L	0.981
11:30952475:C:A	W895C	0.981
11:30952475:C:G	W895C	0.981
11:31306290:G:T	A178D	0.979
11:30881307:A:G	L1692P	0.976
11:30915663:G:C	F1167L	0.976
11:30915663:G:T	F1167L	0.976
11:30915665:A:G	F1167L	0.976
11:30952565:C:A	W865C	0.976
11:30952565:C:G	W865C	0.976

dbSNP variants (sampled 300 via entrez): RS1000001445 (11:31014626 C>T), RS1000014710 (11:30864110 G>A,T), RS1000021246 (11:31288984 C>T), RS1000025336 (11:31260645 C>A,G,T), RS1000029333 (11:31155675 G>A), RS1000031333 (11:31041143 T>A,C,G), RS1000031855 (11:31335578 T>A), RS1000040916 (11:31213583 G>A), RS1000042477 (11:31307608 G>A,C), RS1000044272 (11:31199308 T>A), RS1000054340 (11:31010474 G>T), RS1000064059 (11:31055643 T>A), RS1000066636 (11:30937288 G>A), RS1000069465 (11:31082104 A>C), RS1000071841 (11:31028224 T>C)

Disease associations

OMIM: gene MIM:608062 | disease phenotypes: MIM:106210

GenCC curated gene-disease

Mondo (3): aniridia (MONDO:0019172), aniridia 1 (MONDO:0024507), head and neck cancer (MONDO:0005627)

Orphanet (2): Isolated aniridia (Orphanet:250923), OBSOLETE: Aniridia (Orphanet:77)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

49 associations (top):

Study	Trait	p-value
GCST000494_13	Bone mineral density (spine)	2.000000e-09
GCST000756_1	Magnesium levels	5.000000e-16
GCST001482_7	Lumbar spine bone mineral density	2.000000e-11
GCST001606_1	Renal function-related traits (sCR)	3.000000e-09
GCST001607_2	Renal function-related traits (eGRFcrea)	1.000000e-09
GCST001610_8	Renal function-related traits (BUN)	5.000000e-16
GCST003790_23	Glomerular filtration rate	4.000000e-09
GCST004604_66	Hematocrit	2.000000e-11
GCST004615_71	Hemoglobin concentration	2.000000e-10
GCST005983_38	Serum uric acid levels	1.000000e-08
GCST005984_34	Glomerular filtration rate	8.000000e-22
GCST005985_52	Creatinine levels	3.000000e-21
GCST005986_38	Blood urea nitrogen levels	2.000000e-26
GCST006041_20	Major depressive disorder	8.000000e-08
GCST006627_48	Diastolic blood pressure	3.000000e-11
GCST006979_787	Heel bone mineral density	6.000000e-14
GCST007324_16	Adventurousness	1.000000e-10
GCST007325_15	General risk tolerance (MTAG)	9.000000e-09
GCST007325_276	General risk tolerance (MTAG)	2.000000e-13
GCST007725_18	Serum uric acid levels	8.000000e-10
GCST007733_31	Serum uric acid levels	8.000000e-07
GCST007876_27	Estimated glomerular filtration rate	2.000000e-43
GCST007877_13	Creatinine levels	2.000000e-09
GCST007878_4	Urea levels	5.000000e-08
GCST008058_193	Estimated glomerular filtration rate	3.000000e-115
GCST008059_106	Estimated glomerular filtration rate	1.000000e-91
GCST008060_33	Estimated glomerular filtration rate	8.000000e-18
GCST008062_5	Blood urea nitrogen levels	8.000000e-50
GCST008064_44	Chronic kidney disease	2.000000e-21
GCST008156_136	Hip circumference adjusted for BMI	8.000000e-06

EFO canonical traits (15, from GWAS)

EFO ID	Trait name
EFO:0004845	magnesium measurement
EFO:0004348	hematocrit
EFO:0004509	hemoglobin measurement
EFO:0004761	uric acid measurement
EFO:0006336	diastolic blood pressure
EFO:0009270	heel bone mineral density
EFO:0008579	risk-taking behaviour
EFO:0008039	BMI-adjusted hip circumference
EFO:0009282	sodium measurement
EFO:0004531	urate measurement
EFO:0007787	plasma betaine measurement
EFO:0006939	cup-to-disc ratio measurement
EFO:0004771	visual cortical surface area measurement
EFO:0004346	neuroimaging measurement
EFO:0006935	thalamus volume

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D015783	Aniridia	C11.250.060; C11.270.060; C11.941.375.060; C16.131.384.079; C16.320.290.078

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases methylation, affects cotreatment, increases expression	4
Aflatoxin B1	decreases expression, decreases methylation	3
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
aristolochic acid I	decreases expression	1
methylmercuric chloride	decreases expression	1
methyleugenol	decreases expression	1
bisphenol A	decreases methylation	1
sodium arsenite	increases expression	1
S-(1,2-dichlorovinyl)cysteine	increases expression	1
pentanal	decreases expression	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
bisphenol S	increases methylation	1
jinfukang	increases expression	1
Air Pollutants	decreases expression	1
Aldehydes	decreases expression	1
Benzo(a)pyrene	decreases expression	1
Cadmium	decreases expression, increases abundance	1
Cisplatin	decreases expression	1
N-Nitrosopyrrolidine	decreases expression	1
Silicon Dioxide	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00138827	PHASE4	COMPLETED	Mouth Care Regimes During Radiotherapy
NCT00158041	PHASE4	COMPLETED	Subcutaneous Amifostine Safety Study
NCT00198263	PHASE4	COMPLETED	Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer
NCT00333099	PHASE4	COMPLETED	INEC Study: Immuno-modulating Enteral Nutrition in Cancer
NCT00365508	PHASE4	COMPLETED	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
NCT00666978	PHASE4	COMPLETED	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
NCT00772681	PHASE4	COMPLETED	Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma
NCT00813631	PHASE4	UNKNOWN	The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound
NCT01317589	PHASE4	COMPLETED	Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective?
NCT01418118	PHASE4	COMPLETED	Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
NCT01553032	PHASE4	COMPLETED	Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)
NCT02015650	PHASE4	TERMINATED	Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck
NCT02049112	PHASE4	COMPLETED	A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study
NCT02241083	PHASE4	COMPLETED	The Effect of Norepinephrine and Dopamine on Radial Forearm Free Flap Tissue Oxygen Pressure and Microdialysate Metabolite Measurements
NCT02241876	PHASE4	UNKNOWN	THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS
NCT02597582	PHASE4	COMPLETED	LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients
NCT02622880	PHASE4	COMPLETED	Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients
NCT02880072	PHASE4	COMPLETED	Absorption of Orally Ingested Phosphate in Refeeding Syndrome
NCT02926573	PHASE4	COMPLETED	Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients
NCT03607227	PHASE4	COMPLETED	Continous Popliteal Block for Microvascular Free Flap Reconstruction in Ear, Nose and Throat Surgery
NCT03714867	PHASE4	WITHDRAWN	Pre-Operative Pregabalin for Post-Operative Pain in Head and Neck Cancer Surgery
NCT04155008	PHASE4	TERMINATED	Nutrition and Pharmacological Algorithm for Oncology Patients Study
NCT04246697	PHASE4	COMPLETED	Multimodal Pain Study in Free Flap Patients
NCT04292990	PHASE4	UNKNOWN	Comparison of Transdermal Fentanyl and Morphine for Oral Mucositis Pain in Nasopharyngeal Cancer Patients
NCT04507035	PHASE4	UNKNOWN	Treating Locally Advanced Head and Neck Malignant Tumor With Anlotinib and Chemoradiotherapy
NCT04977271	PHASE4	WITHDRAWN	Mood Disorders in Head and Neck Cancer Patients
NCT05046028	PHASE4	COMPLETED	Individualization of Nutritive Sensory Support Of Radiation Therapy
NCT05055726	PHASE4	COMPLETED	Benzydamine Oromucosal Solution in Oral Mucositis (BOOM)
NCT06521697	PHASE4	NOT_YET_RECRUITING	Effects of Minimal-Flow Sevoflurane and Multimodal Analgesia in Head and Neck Cancer Surgery
NCT06734598	PHASE4	RECRUITING	Efficacy of Botox Injection of the Masticatory Muscles in Head &Neck Cancer Patients with Trismus After Radiotherapy
NCT06807034	PHASE4	ACTIVE_NOT_RECRUITING	Impact of the Oral Microbiota on Relapse in HNSCC Patients
NCT06879691	PHASE4	ACTIVE_NOT_RECRUITING	A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma
NCT07158164	PHASE4	RECRUITING	DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
NCT07189897	PHASE4	RECRUITING	Apixaban or Enoxaparin After Head and Neck Cancer Surgery
NCT00002476	PHASE3	COMPLETED	Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer
NCT00002496	PHASE3	COMPLETED	Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Cancer of the Larynx
NCT00002507	PHASE3	COMPLETED	Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
NCT00002555	PHASE3	COMPLETED	High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer
NCT00002654	PHASE3	COMPLETED	Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer
NCT00002659	PHASE3	UNKNOWN	Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer